NVCT vs. AMLX, KPTI, FGEN, SYRS, SGMT, VTGN, PDSB, DMAC, RPTX, and ABEO
Should you be buying Nuvectis Pharma stock or one of its competitors? The main competitors of Nuvectis Pharma include Amylyx Pharmaceuticals (AMLX), Karyopharm Therapeutics (KPTI), FibroGen (FGEN), Syros Pharmaceuticals (SYRS), Sagimet Biosciences (SGMT), Vistagen Therapeutics (VTGN), PDS Biotechnology (PDSB), DiaMedica Therapeutics (DMAC), Repare Therapeutics (RPTX), and Abeona Therapeutics (ABEO). These companies are all part of the "pharmaceutical preparations" industry.
Amylyx Pharmaceuticals (NASDAQ:AMLX) and Nuvectis Pharma (NASDAQ:NVCT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, community ranking, earnings, profitability and analyst recommendations.
Nuvectis Pharma has a net margin of 0.00% compared to Nuvectis Pharma's net margin of -17.86%. Nuvectis Pharma's return on equity of 4.14% beat Amylyx Pharmaceuticals' return on equity.
In the previous week, Nuvectis Pharma had 6 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 14 mentions for Nuvectis Pharma and 8 mentions for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 1.05 beat Nuvectis Pharma's score of 0.14 indicating that Nuvectis Pharma is being referred to more favorably in the news media.
Amylyx Pharmaceuticals presently has a consensus target price of $28.67, suggesting a potential upside of 1,466.48%. Nuvectis Pharma has a consensus target price of $21.00, suggesting a potential upside of 241.46%. Given Nuvectis Pharma's higher probable upside, equities research analysts plainly believe Amylyx Pharmaceuticals is more favorable than Nuvectis Pharma.
Amylyx Pharmaceuticals received 17 more outperform votes than Nuvectis Pharma when rated by MarketBeat users. However, 88.89% of users gave Nuvectis Pharma an outperform vote while only 62.50% of users gave Amylyx Pharmaceuticals an outperform vote.
95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 96.8% of Nuvectis Pharma shares are owned by institutional investors. 11.7% of Amylyx Pharmaceuticals shares are owned by insiders. Comparatively, 38.9% of Nuvectis Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Amylyx Pharmaceuticals has higher revenue and earnings than Nuvectis Pharma. Nuvectis Pharma is trading at a lower price-to-earnings ratio than Amylyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Amylyx Pharmaceuticals has a beta of -0.68, indicating that its stock price is 168% less volatile than the S&P 500. Comparatively, Nuvectis Pharma has a beta of 0.45, indicating that its stock price is 55% less volatile than the S&P 500.
Summary
Amylyx Pharmaceuticals beats Nuvectis Pharma on 9 of the 17 factors compared between the two stocks.
Get Nuvectis Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for NVCT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NVCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nuvectis Pharma Competitors List
Related Companies and Tools
